July 9, 2019

Avidea co-authors publication on combining therapeutic cancer vaccines with oncolytic virotherapy

Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance


June 17, 2019


June 15, 2019

Avidea co-authors publication on intravenously administered nanomedicines for enhanced cancer immunotherapy in Cancer Letters

Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines


May 23, 2019

Avidea speaks at TIDES: Oligonucleotide and Peptide Therapeutics conference, San Diego, CA

Improving Formulation Consistency of Individualized, Peptide-based Therapies Using Self-assembling Nanoparticles




March 7, 2019

Avidea speaks at the CRUK Cambridge Institute Radical Approaches to Cancer Prevention meeting, Cambridge, United Kingdom

Self-assembling nanoparticles delivering tumor antigens and TLR-7/8 agonist induce broad CD8 T cell immunity


January 23, 2019

Avidea collaborator presents on the SNP-7/8a platform at the Keystone Conference:  Cancer Vaccines, Vancouver, Canada

Peptide-TLR-7/8 Agonist Vaccines Chemically Programmed to Enhance the Magnitude, Quality, and Breadth of Neoantigen CD8 T Cell Responses


January 22, 2019

Avidea collaborator presents on the SNP-7/8a platform at the Keystone Conference:  Cancer Vaccines, Vancouver, Canada

Route, Dose, and Agonist Potency Influence the Induction of Tcf-1+ Neoantigen-Specific CD8 T Cells by Peptide-TLR-7/8 Agonist Nanoparticle Vaccine


January 4, 2019

Avidea co-authors publication on polymer-TLR-7/8 agonist compositions for inducing CD8 T cell responses in ACS journal Biomacromolecules

Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction


November 16, 2018

Avidea presents a plenary session at the 2018 NeoAg Summit, Boston, MA

Improved induction of neoantigen-specific T cells with self-assembling nanoparticles



October 2, 2018

Avidea collaborator presents on the SNP-7/8a platform at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York City, NY

Peptide-TLR-7/8 agonist conjugate vaccines chemically programmed for nanoparticle self-assembly enhance the magnitude and breadth of anticancer neoantigen CD8 T cell immunity


September 20, 2018

Avidea speaks at Bio+Tech18 Conference, Baltimore, MD

Cancer Immunotherapeutics session


May 23, 2018

Darrell Irvine, MIT Professor of Materials Science and Engineering, writes that Avidea’s technology linking TLR agonists to polymers is a “promising approach” to vaccine development in Nature Materials.

Material aid for vaccines


April 23, 2018

Avidea speaks at BioHealth Capital Region Forum 2018, Gaithersburg, MD

Universities:  From research to commercialization


April 15, 2018

Avidea collaborator presents a plenary session on the SNP-7/8a platform at AACR, Chicago, IL

Personalized therapies:  Neoantigen discovery and vaccination


April 11, 2018

Avidea collaborator presents on the SNP-7/8a platform at the Keystone Conference:  Myeloid Cells, Breckenridge, CO

Targeting Dendritic Cells and Monocytes with a Nanoparticle Neoantigen-TLR7/8 Agonist Vaccine Induces Anti-Tumor CD8 T Cell Immunity



January 20, 2018

Avidea collaborator presents on the SNP-7/8a platform at the Keystone Conference:  T Cell Dysfunction, Cancer and Infection, Breckenridge, CO

Adjuvants for T Cell Vaccines